METABOLIC SYNDROME VS INSULIN RESISTANCE SYNDROME (A CLUSTER OF COMPONENTS AND STRATEGIES FOR TREATMENT)
ABSTRACT: Metabolic Syndrome =
MS (in which abdominal Obesity is the culprit of the MS) is defined by NCEP-ATP
III in 2001, whereas Dysmetabolic Syndrome = DMS and Insulin Resistance
Syndrome = IRS are recommended terms by AACE (in 2002) and ACE (in 2002),
respectively. Both AACE and ACE stated that insulin resistance plays central
role in the syndrome. All these terms of the syndrome are originally and
firstly coined by Reaven as Syndrome-X in 1988, and then Metabolic Syndrome-X in
1999. Either MS or DMS or IRS has become major issues because of its impact on
the risks of Type 2 DM (T2DM) development and cardiovascular diseases. The
criteria of MS, IRS (including its risk factors), and the clusters of
components belong to MS and IRS, are listed in this paper. Rational strategies
for the treatment of MS and IRS are focused on obesity and insulin resistance,
respectively, and can be summarized as follows: A. Improving insulin
sensitivity and lifestyle (weight loss 5-10%, aerobic exercise ± 30-40 min, 4
times/week). B. Pharmacological Interventions directed to the targets for
(mmHg, ml/dl): Blood Pressure < 130/85, and 130/80 in diabetic patients, Fasting
Plasma Glucose (FPG) < 110 or 2 Hour Post-75
Glucose Challenge < 140, Triglyceride (TG) < 150, and HDL-Cholesterol
> 40 for men, and > 50 for women. Clinical evidence-based data supported,
that Metformin (UKPDS Outcomes), Sibutramine (STORM Landmark Trial), and
Orlistat (XENDOS Study), to date, are the promising drugs for the treatment of
MS/IRS. However, the drugs specifically
to improve the insulin sensitivity are hoped to treat this Syndrome.
Conclusions: Syndrome-X, Metabolic Syndrome-X, MS, DMS, or IRS, all have become
major issues because of their roles in the development of either T2DM or
Cardiovascular Diseases. The cluster of components of this Syndrome and its
risk factors should be well recognized. Improving insulin sensitivity, losing
body weight, aerobic exercise, and pharmacologic interventions (Metformin, Sibutramin,
Orlistat) are rational strategies for the treatment of MS/IRS.
Keywords: metabolic syndrome,
dysmetabolic syndrome, insulin resistance syndrome, type 2 diabetes mellitus, cardiovascular
diseases
Author: Askandar Tjokroprawiro
Journal Code: jpkedokterangg050020
